StreetInsider.com News Articles

Dermata launches first Tome skincare product for consumers

Tue, 25 Aug 2026 08:31:17 -0400

Dermata Therapeutics (NASDAQ: DRMA) has launched its first direct-to-consumer skincare product, the Tome Foundational Treatment, the company announced in a press release dated August 25, 2026.

The product is available for purchase at the company's website as either a one-time purchase or through a monthly subscription at a discounted price. The treatment is designed to be used once weekly and is intended to improve skin tone and texture over time.

The Foundational Treatment uses an ingredient the company calls Bioneedle, described as a purified powder derived from Spongilla lacustris, a freshwater sponge. Dermata says the ingredient is wild harvested and minimally processed.

Gerry

Dermata Therapeutics Announces Commercial Launch of Tome Foundational Treatment

Tue, 25 Aug 2026 08:30:00 -0400

- Tome Foundational Treatment, powered by Bioneedle™, is now available for purchase at www.tomeskincare.com -

- Once-weekly Foundational Treatment is designed to renew the appearance of skin and improve tone and texture over time -

- Consumers can purchase a one-month kit or subscribe for convenient recurring delivery -

SAN DIEGO, CA / ACCESS Newswire / August 25, 2026 / Dermata Therapeutics, Inc. (Nasdaq:DRMA) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today announced the official commercial launch of the Tome Foundational Treatment, the first product available for purchase under the Company's

Dermata Therapeutics Announces Commercial Launch of Tome Foundational Treatment

Tue, 25 Aug 2026 08:30:00 -0400

- Tome Foundational Treatment, powered by Bioneedle™, is now available for purchase at www.tomeskincare.com -

- Once-weekly Foundational Treatment is designed to renew the appearance of skin and improve tone and texture over time -

- Consumers can purchase a one-month kit or subscribe for convenient recurring delivery -

Dermata opens preorders for Tome skincare product at $178

Fri, 21 Aug 2026 08:30:11 -0400

Dermata Therapeutics (NASDAQ: DRMA) announced that preorders are now open for its Tome Foundational Treatment, a once-weekly topical skin mask, with shipping expected to begin August 25, 2026.

The product retails for $178 per unit, which the company says equates to approximately $45 per treatment. Subscribers receive a 10% discount. Each purchase includes four once-weekly treatments, with each treatment containing a cup of the company's Bioneedle powder, a tube of Activator, and an application brush. Consumers mix the product before applying it as a mask.

The Tome Foundational Treatment is described by the company as its first direct-to-consumer skincare product and the

Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch

Fri, 21 Aug 2026 08:30:00 -0400

- Preorders can be made by visiting www.tomeskincare.com -

- Dermata is ready to begin shipping orders on the expected launch date of August 25, 2026 -

- Tome Foundational Treatment is a once-weekly topical mask for skin renewal -

SAN DIEGO, CA / ACCESS Newswire / August 21, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced that Tome Foundational Treatment, the Company's first direct-to-consumer skincare product, is now open to preorders. The Tome Foundational Treatment is expected to start shipping on

Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch

Fri, 21 Aug 2026 08:30:00 -0400

- Preorders can be made by visiting www.tomeskincare.com -

- Dermata is ready to begin shipping orders on the expected launch date of August 25, 2026 -

- Tome Foundational Treatment is a once-weekly topical mask for skin renewal -

Form 4 Dermata Therapeutics, For: Aug 16 Filed by: PROEHL GERALD T

Tue, 18 Aug 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20260818/26945537.html

Form 4 Dermata Therapeutics, For: Aug 16 Filed by: PROEHL GERALD T

Tue, 18 Aug 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20260818/26945537.html

Form 4 Dermata Therapeutics, For: Aug 16 Filed by: Van Hoose Kyri K.

Tue, 18 Aug 2026 17:22:00 -0400

si-local-file:///var/storage/secattach/20260818/26945502.html

Form 4 Dermata Therapeutics, For: Aug 16 Filed by: Van Hoose Kyri K.

Tue, 18 Aug 2026 17:22:00 -0400

si-local-file:///var/storage/secattach/20260818/26945502.html

Form 25-NSE Dermata Therapeutics, Filed by: Nasdaq Stock Market LLC

Mon, 17 Aug 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260817/26938234.html

Form 25-NSE Dermata Therapeutics, Filed by: Nasdaq Stock Market LLC

Mon, 17 Aug 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260817/26938234.html

Dermata Therapeutics raises $3.4M in private placement

Mon, 17 Aug 2026 08:31:41 -0400

Dermata Therapeutics, Inc. (NASDAQ: DRMA) has entered into definitive agreements for a private placement priced at-the-market under Nasdaq rules, according to a company statement.

The offering includes 2,293,608 shares of common stock, or pre-funded warrants in lieu thereof, at a purchase price of $1.46 per share. The offering also includes series E warrants and series F warrants, each to purchase up to 2,293,608 shares of common stock, with an exercise price of $1.46 per share.

The series E warrants expire five years from the effective date of stockholder approval, while the series F warrants expire 24 months from that date. Both warrant

Form 8-K Dermata Therapeutics, For: Aug 16

Mon, 17 Aug 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260817/26935371.html

Form 8-K Dermata Therapeutics, For: Aug 16

Mon, 17 Aug 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260817/26935371.html

Dermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Mon, 17 Aug 2026 08:30:00 -0400

$3.4 million upfront with up to approximately $6.7 million of potential additional gross proceeds upon the exercise in full of warrants

SAN DIEGO, CA / ACCESS Newswire / August 17, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 2,293,608 shares of common stock (or pre-funded warrants in lieu thereof), series E warrants to purchase up to 2,293,608 shares of common stock and short-term series F warrants

Dermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Mon, 17 Aug 2026 08:30:00 -0400

$3.4 million upfront with up to approximately $6.7 million of potential additional gross proceeds upon the exercise in full of warrants

Dermata Therapeutics, Inc (DRMA) Misses Q2 EPS by 19c

Tue, 11 Aug 2026 16:56:57 -0400

Dermata Therapeutics, Inc (NASDAQ: DRMA) reported Q2 EPS of ($0.74), $0.19 worse than the analyst estimate of ($0.55).

For earnings history and earnings-related data on Dermata Therapeutics, Inc (DRMA) click here.

Form 10-Q Dermata Therapeutics, For: Jun 30

Tue, 11 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260811/26905710.html

Form 10-Q Dermata Therapeutics, For: Jun 30

Tue, 11 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260811/26905710.html

Form 8-K Dermata Therapeutics, For: Aug 11

Tue, 11 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260811/26905673.html

Form 8-K Dermata Therapeutics, For: Aug 11

Tue, 11 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260811/26905673.html

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026

Tue, 11 Aug 2026 16:05:00 -0400

- Dermata announced the launch date of its first commercial product, Tome™ Foundational Treatment, expected on August 25, 2026 -

- Dermata recently attended Be+Well Beauty and Wellness Show in Las Vegas, NV to announce the Tome brand -

SAN DIEGO, CA / ACCESS Newswire / August 11, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today highlighted recent corporate progress and reported financial results for the second quarter ended June 30, 2026.

"Over the past year, we have transformed Dermata through

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026

Tue, 11 Aug 2026 16:05:00 -0400

- Dermata announced the launch date of its first commercial product, Tome™ Foundational Treatment, expected on August 25, 2026 -

- Dermata recently attended Be+Well Beauty and Wellness Show in Las Vegas, NV to announce the Tome brand -

"Over the past year, we have transformed Dermata through

Dermata Therapeutics to launch first consumer skincare product Aug. 25

Wed, 05 Aug 2026 08:30:13 -0400

Dermata Therapeutics, Inc. (NASDAQ: DRMA) announced that its Tome Foundational Treatment, the company's first direct-to-consumer skincare product, is planned to launch on August 25, 2026, priced at $178 per set, or approximately $45 per treatment.

The product will be sold exclusively through tomeskincare.com. Consumers who join a waitlist will receive early access to preorder. The set includes four once-weekly treatments, each consisting of a cup of Bioneedle powder, a tube of Activator solution, and a brush for at-home application.

The Tome Foundational Treatment features the company's proprietary Bioneedle technology, which uses a wild-harvested freshwater sponge called Spongilla lacustris. The product is applied